SecBot SecBot
PRESS-RELEASE ·Filed Aug 10, 2026

GRFS

Grifols, S.A.
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

No efficacy data released yet; the stock is unlikely to move until topline results in late 2026. Monitor for any early leaks or presentations at medical conferences. The SWIFT-SC subcutaneous program adds optionality but remains early-stage.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.05
T+0 close · Aug 10, 2026 · via day close
Latest settled
+6.34%
T+60 · $8.56
Vs SPY
+8.75%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 10 $8.05entry
  2. T+1 · 3mo ago −0.75%α −0.43% · $7.99
  3. T+5 · 3mo ago −3.48%α −3.43% · $7.77
  4. T+20 · 2mo ago −3.73%α −2.81% · $7.75
  5. T+60 · 14d ago +6.34%α +8.75% · $8.56
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Grifols announced completion of the clinical portion (last patient, last visit) of its Phase 3 SPARTA trial evaluating Prolastin-C in alpha-1 antitrypsin deficiency patients with emphysema. Topline results are expected by the end of 2026. This is a pipeline milestone with no financial data or efficacy readout yet.

Key Facts

  • SPARTA Phase 3 trial completed last-patient-last-visit; topline results expected by end of 2026.
  • Trial enrolled 345 participants across 37 sites in 16 countries.
  • Evaluates two dose regimens of Prolastin-C (60 mg/kg and 120 mg/kg) vs placebo over three years.
  • Primary endpoint is whole-lung CT densitometry, a sensitive measure of emphysema progression.
  • Grifols also initiated SWIFT-SC Phase 3 trial for a subcutaneous alpha-1 proteinase inhibitor.

Financial Impact

No financial figures disclosed; commercial impact depends on topline results expected year-end 2026.

Risk Factors

  • Topline results may fail to show statistically significant efficacy on CT densitometry endpoint.
  • Even if positive, label expansion and market adoption for Prolastin-C may be limited.
  • Competition from other augmentation therapies and subcutaneous formulations.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3341676

Track record

7 reports on GRFS

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $8.51 to $8.69 Now $8.69 +2.12% ▲ +2.12% +2.04% vs SPY
  2. Nov 2, 202614d ago 6-K Bullish 6/10 Entry $8.51 to $8.69 Now $8.69 +2.12% ▲ +2.12% +2.04% vs SPY
  3. Aug 10, 202614w ago Press Release Neutral 4/10 Viewing Entry $8.05 to $7.77 Now $8.69 +7.95% ▼ −3.48% −3.43% vs SPY
  4. Jul 30, 202615w ago 6-K Neutral 2/10 Entry $8.20 to $7.83 Now $8.69 +5.98% ▼ −4.51% −8.13% vs SPY
  5. Jul 16, 202617w ago Press Release Neutral 4/10 Entry $7.33 to $7.54 Now $8.69 +18.55% ▲ +2.86% +4.54% vs SPY
  6. Jun 18, 202621w ago 6-K Neutral 3/10 Entry $7.28 to $7.39 Now $8.69 +19.37% ▲ +1.51% +3.58% vs SPY
  7. Mar 17, 202634w ago Press Release Bullish 7/10 Entry $8.02 to $7.60 Now $8.69 +8.35% ▼ −5.24% −2.58% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens Wed (12h 10m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026